Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Glycosaminoglycan Polysulfate→

Glycosaminoglycan Polysulfate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
9082-07-9
Molecular formula
Not available
Molecular weight
Not available
Drug class
Heparinoid glycosaminoglycantopical anti-inflammatory and antiexudative agent
Mechanism of action
Mucopolysaccharide polysulfate has local heparinoid, anti-inflammatory, anti-exudative and fibrinolytic properties. The UK product information describes weak inhibition of prostaglandin E2 synthesis, an indirect effect on leukotriene B4, potentiation of urokinase activity and inhibition of hyaluronidase.
Indications / reported uses
  • Used as a component of topical salicylic acid/mucopolysaccharide polysulfate products for symptomatic relief of muscular pain and stiffness, sprains, strains and pain due to rheumatic and non-serious arthritic conditions. It is not a stand-alone systemic anticoagulant indication.

Sources: https://www.medicines.org.uk/emc/product/1352/smpc · https://www.medicines.org.uk/emc/product/1351/smpc · https://www.ndf.gov.sg/about-drugs/active-ingredient/m00249/ · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Heparinoid glycosaminoglycan; topical anti-inflammatory and antiexudative agent

Mechanism of action

Mucopolysaccharide polysulfate has local heparinoid, anti-inflammatory, anti-exudative and fibrinolytic properties. The UK product information describes weak inhibition of prostaglandin E2 synthesis, an indirect effect on leukotriene B4, potentiation of urokinase activity and inhibition of hyaluronidase.

General use cases

  • Used as a component of topical salicylic acid/mucopolysaccharide polysulfate products for symptomatic relief of muscular pain and stiffness, sprains, strains and pain due to rheumatic and non-serious arthritic conditions. It is not a stand-alone systemic anticoagulant indication.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Glycosaminoglycan Polysulfate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Glycosaminoglycan Polysulfate Permitted Daily Exposure (PDE) report (the Glycosaminoglycan Polysulfate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Glycosaminoglycan Polysulfate Occupational Exposure Limit (OEL) report (the Glycosaminoglycan Polysulfate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.